Answers are grounded in this paper and cite their sources.
Bioengineered curcumin and SCFA nanoparticles improve epithelial barrier and reduce inflammation in radiation enteritis, indicating potential therapeutic benefits.
Radiation enteritis (RE) is a common side effect of abdominal radiotherapy, which causes intestinal inflammation and impairment of epithelial barrier. In this study, we developed a bioengineered dual-delivery nanosystem by encapsulating curcumin and microbiota-derived short-chain fatty acids (SCFAs: acetate, propionate, and butyrate) into PLGA nanoparticles (Cur-PLGA NPs@SCFAs). The formulation encapsulated 66% of curcumin and released it slowly over 48 h, with about 72.6% of it being released at pH 7.4. In vitro studies using Caco-2 cells, the Cur-PLGA NPs@SCFAs maintained good cytocompatibility, with cell viability over 81.5% at 40 µg/mL as well as reduced intracellular reactive oxygen species to 65.1% of control levels. Wound closure reached 86.2% at 48 h whereas compared to untreated cells (42.7%). In vivo mice model, high-dose administration (40 mg/kg) markedly improved disease outcomes, reducing the Disease Activity Index to 3.8 ± 0.4 compared with 8.6 ± 0.5 in the RE group, while restoring colon length (7.1 ± 0.2 cm) and spleen index (0.29 ± 0.01%). Pro-inflammatory mediators IL-6 and TNF-α were decreased, accompanied by suppression of NF-κB p65 signaling, whereas IL-10 and the tight junction proteins ZO-1 and occludin were increased. Antioxidant defenses (GSH, SOD, and T-AOC) were recovered, and cecal SCFA levels were nearly doubled, collectively indicating a protective effect on intestinal inflammation and barrier integrity.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: